BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dong Y, Liu TH, Yau T, Hsu C. Novel systemic therapy for hepatocellular carcinoma. Hepatol Int 2020;14:638-51. [PMID: 32661949 DOI: 10.1007/s12072-020-10073-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Tu K, Li J, Mo H, Xian Y, Xu Q, Xiao X. Identification and validation of redox-immune based prognostic signature for hepatocellular carcinoma. Int J Med Sci 2021;18:2030-41. [PMID: 33850474 DOI: 10.7150/ijms.56289] [Reference Citation Analysis]
2 Su YY, Li CC, Lin YJ, Hsu C. Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives. Semin Liver Dis 2021;41:263-76. [PMID: 34130338 DOI: 10.1055/s-0041-1730949] [Reference Citation Analysis]
3 Zhao E, Chen S, Dang Y. Development and External Validation of a Novel Immune Checkpoint-Related Gene Signature for Prediction of Overall Survival in Hepatocellular Carcinoma. Front Mol Biosci 2020;7:620765. [PMID: 33553243 DOI: 10.3389/fmolb.2020.620765] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Cucarull B, Tutusaus A, Hernáez-Alsina T, García de Frutos P, Reig M, Colell A, Marí M, Morales A. Antioxidants Threaten Multikinase Inhibitor Efficacy against Liver Cancer by Blocking Mitochondrial Reactive Oxygen Species. Antioxidants (Basel) 2021;10:1336. [PMID: 34572967 DOI: 10.3390/antiox10091336] [Reference Citation Analysis]